KMT2A and leukemia: We transplanted MLL-AF9 AML cells with forced expression of Alox5 (i.e., MA9_Alox5) or without (i.e., MA9) into secondary recipient mice, and after the onset of leukemia, the recipient mice were treated with or without DOX + Ara-C (i.e. “5 + 3” regimen5).